Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Baudax Bio Inc. (BXRX)

1.3   -0.03 (-2.26%) 01-17 17:22
Open: 1.31 Pre. Close: 1.33
High: 1.37 Low: 1.28
Volume: 3,317,364 Market Cap: 55M
Baudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care settings. Its lead product candidate is intravenous form of meloxicam, a non-opioid that has completed Phase III clinical trials for the management of moderate to severe pain; and is in the Phase IIIb clinical trials in colorectal surgery and orthopedic surgery patients to assess opioid consumption, pain intensity, and length of hospital stay with associated pharmacoeconomic parameters. The company's early-stage product candidates includes RP1000, an intermediate-acting neuromuscular blocking agent (NMBA) that is in phase I clinical trial; and RP2000, an ultrashort-acting NMBA, which is in pre-clinical trial; and a reversal agent, as well as Dex-IN, a proprietary intranasal formulation of dexmedetomidine. The company was incorporated in 2019 and is based in Malvern, Pennsylvania.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 1.372 - 1.379 1.379 - 1.385
Low: 1.265 - 1.272 1.272 - 1.277
Close: 1.29 - 1.301 1.301 - 1.31

Technical analysis

as of: 2021-01-15 4:38:29 PM
Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected.
Target: Six months: 1.68     One year: 1.96
Support: Support1: 1.15    Support2: 0.97
Resistance: Resistance1: 1.44    Resistance2: 1.68
Pivot: 1.14
Moving Average: MA(5): 1.32     MA(20): 1.11
MA(100): 1.88     MA(250): 3.42
MACD: MACD(12,26): 0.04     Signal(9):
Stochastic oscillator: %K(14,3): 73.17     %D(3): 77.45
RSI: RSI(14): 63.09
52-week: High: 10.14  Low: 0.97  Change(%): -81.5
Average Vol(K): 3-Month: 318735  10-Days: 698295

Price, moving averages and Bollinger Bands

Price and moving averages has closed above its Short term moving average. Short term moving average is currently above mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
BXRX has closed below upper band by 21.2%. Bollinger Bands are 31.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

Wed, 13 Jan 2021
Do Traders View Baudax Bio Inc (BXRX) Stock's Current Trend Positively? - InvestorsObserver

Tue, 12 Jan 2021
Premarket Mover: Baudax Bio Inc (BXRX) Up 5.38% - InvestorsObserver

Mon, 11 Jan 2021
Premarket Mover: Baudax Bio Inc (BXRX) Up 5.13% - InvestorsObserver

Thu, 07 Jan 2021
Baudax Bio to Present at the H.C. Wainwright BioConnect 2021 Conference - MyChesCo

Wed, 06 Jan 2021
Baudax Bio Inc (BXRX) Up 6.00% in Premarket Trading - InvestorsObserver

Sat, 19 Dec 2020
Baudax Bio Announces $12 Million Offering Priced at a Premium to Market - MyChesCo

Financial Analysis

Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Price to Book Value: Underperform Discounted cash flow: Outperform
Return on Assets: Outperform Price to Earnings: Outperform
Return on Equity: Underperform Debt to Equity: Underperform
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 43
Shares Float (M) 24
% Held by Insiders 0.51
% Held by Institutions 18.96
Shares Short (K) 1,380
Shares Short P. Month (K) 659

Stock Financials

EPS Est This Year
EPS Est Next Year
Book Value (p.s.)
Profit Margin
Operating Margin -11481.05
Return on Assets (ttm) -61.4
Return on Equity (ttm)
Qtrly Rev. Growth
Gross Profit (p.s.)
Sales Per Share 0.010
EBITDA (p.s.) -1.113
Qtrly Earnings Growth
Operating Cash Flow (M) -37
Levered Free Cash Flow (M) -7

Stock Valuations

PE Ratio
PEG Ratio
Price to Book value
Price to Sales 132.93
Price to Cash Flow -1.48

Stock Dividends

Forward Dividend
Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
Stock Chart
Stoxline Lite
Stoxline Pro
Option Calculator
(c) 2006-2020 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.